Cargando...
Targeting HER2 Positive Breast Cancer with Chemopreventive Agents
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is a subtype of breast cancer that is exhibited in approximately 20-30% of breast cancer cases. The overexpression of HER2 is typically associated with a more aggressive disease and poor prognosis. Currently, the therapeutic dru...
Gardado en:
| Publicado en: | Curr Pharmacol Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4591552/ https://ncbi.nlm.nih.gov/pubmed/26442201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40495-015-0040-z |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|